6-(3,5-Dimethoxy-phenyl)-cyclohex-3-en-1-on | 89261-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(3,5-Dimethoxy-phenyl)-cyclohex-3-en-1-on
• 英文别名: 2-(3,5-dimethoxyphenyl)-4-cyclohexen-1-one；6-(3,5-Dimethoxyphenyl)-3-cyclohexen-1-one；3',5'-Dimethoxy-3,6-dihydro[1,1'-biphenyl]-2(1H)-one；6-(3,5-dimethoxyphenyl)cyclohex-3-en-1-one
• CAS: 89261-30-3
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: AINVITCTUIQCJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(3,5-Dimethoxy-phenyl)-cyclohex-3-en-1-on 生成 2-(3,5-Dimethoxyphenyl)cyclohexanone
  参考文献：
  名称：

  EGGLER, J. F.;JOHNSON, M. R.;MELVIN, L. S. ,, JR.

  摘要：

  DOI：
• 作为产物：
  描述：

  5-Nitro-4-(3,5-dimethoxyphenyl)-cyclohex-1-en 生成 6-(3,5-Dimethoxy-phenyl)-cyclohex-3-en-1-on
  参考文献：
  名称：

  EGGLER, J. F.;JOHNSON, M. R.;MELVIN, L. S. ,, JR.

  摘要：

  DOI：

文献信息

• Substituted hexahydropyrrolo[1,2-a]-quinolines, hexahydro-1H-pyrido[1,2-a]-
  申请人：Pfizer Inc.

  公开号：US04476131A1

  公开（公告）日：1984-10-09

  Tricyclic benzo fused compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, wherein n is zero, 1 or 2, and t is 1 or 2; M is CH or N, R.sub.1 is H or certain acyl groups; Q is CO.sub.2 R.sub.4, COR.sub.5, C(OR.sub.7)R.sub.5 R.sub.6, CN, CONR.sub.9 R.sub.10, CH.sub.2 NR.sub.9 R.sub.10, CH.sub.2 NHCOR.sub.11, CH.sub.2 NHSO.sub.2 R.sub.12, 5-tetrazolyl or when n is 1, Q and OR.sub.1 together form a lactone or certain reduced derivatives thereof; and Z is certain alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl groups, are valuable central nervous system active agents, methods for their use, pharmaceutical compositions containing them and certain intermediates therefor.

  三环苯并化合物的结构式为##STR1##及其药学上可接受的阳离子和酸盐，其中n为零、1或2，t为1或2；M为CH或N，R.sub.1为H或特定的酰基；Q为CO.sub.2 R.sub.4、COR.sub.5、C(OR.sub.7)R.sub.5 R.sub.6、CN、CONR.sub.9 R.sub.10、CH.sub.2 NR.sub.9 R.sub.10、CH.sub.2 NHCOR.sub.11、CH.sub.2 NHSO.sub.2 R.sub.12、5-四唑基或当n为1时，Q和OR.sub.1共同形成内酯或其还原衍生物；Z为特定的烷基、烷氧基、烷氧基烷基、芳基烷基、芳基氧基、芳基氧基烷基或芳基烷氧基烷基基团，是有价值的中枢神经系统活性剂，其使用方法、含有它们的药物组合物以及某些中间体。
• Substituted hexahydrobenzo[e]indene and octahydrophenanthrene CNS agents
  申请人：Pfizer Inc.

  公开号：US04576964A1

  公开（公告）日：1986-03-18

  Tricyclic benzo fused compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, wherein n is zero, 1 or 2, and t is 1 or 2; M is CH or N, R.sub.1 is H or certain acyl groups; Q is CO.sub.2 R.sub.4, COR.sub.5, C(OR.sub.7)R.sub.5 R.sub.6, CN, CONR.sub.9 R.sub.10, CH.sub.2 NR.sub.9 R.sub.10, CH.sub.2 NHCOR.sub.11, CH.sub.2 NHSO.sub.2 R.sub.12, 5-tetrazolyl or when n is 1, Q and OR.sub.1 together form a lactone or certain reduced derivatives thereof; and Z is certain alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl groups, are valuable central nervous system active agents, methods for their use, pharmaceutical compositions containing them and certain intermediates therefor.

  公式为##STR1##的三环苯并化合物及其药学上可接受的阳离子和酸加成盐，其中n为0、1或2，t为1或2；M为CH或N，R.sub.1为H或某些酰基基团；Q为CO.sub.2 R.sub.4、COR.sub.5、C(OR.sub.7)R.sub.5 R.sub.6、CN、CONR.sub.9 R.sub.10、CH.sub.2 NR.sub.9 R.sub.10、CH.sub.2 NHCOR.sub.11、CH.sub.2 NHSO.sub.2 R.sub.12、5-四唑基或当n为1时，Q和OR.sub.1共同形成内酯或其某些还原衍生物；Z为某些烷基、烷氧基、烷氧基烷基、芳基烷基、芳基氧基烷基或芳基氧基烷基基团，是有价值的中枢神经系统活性剂，其使用方法、含有它们的药物组合物和某些中间体。
• Substituted hexahydropyrrolo(1,2-a)-quinoline, hexahydro-1H-pyrido(1,2-a)-quinoline, hexahydrobenzo(3)indene and octahydrophenanthrene CNS agents
  申请人：PFIZER INC.

  公开号：EP0090516A1

  公开（公告）日：1983-10-05

  Tricyclic benzo fused compounds of the formula and pharmaceutically acceptable cationic and acid addition salts thereof, wherein n is zero, 1 or 2, and t is 1 or 2; M is CH or N, R1 is H or certain acyl groups; Q is CO2R4, CORS, C(OR7)R5R6, CN, CONR9R10, CH2NR9R10, CH2NHCOR11, CH2NHSO2R12, 5-tetrazolyl or when n is 1, Q and OR1 together form a lactone or certain reduced derivatives thereof; and Z is certain alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl groups, are valuable central nervous system active agents, methods for their use, pharmaceutical compositions containing them and certain intermediates therefor.

  式中的三环苯并融合化合物 及其药学上可接受的阳离子盐和酸加成盐，其中 n 为零、1 或 2，t 为 1 或 2；M 为 CH 或 N，R1 为 H 或某些酰基；Q 为 CO2R4、CORS、C(OR7)R5R6、CN、CONR9R10、CH2NR9R10、CH2NHCOR11、CH2NHSO2R12、5-四唑基，或当 n 为 1 时，Q 和 OR1 共同形成内酯或其某些还原衍生物；和 Z 是某些烷基、烷氧基、烷氧基烷基、芳基、芳氧基烷基或芳氧基烷基，这些都是有价值的中枢神经系统活性剂、使用方法、含有它们的药物组合物及其某些中间体。
• Substituted dodecahydrotriphenylenes, decahydro-1H-cyclopenta(1)phenanthrenes, decahydro-1H-pyrido(1,2-f)phenanthridines and decahydropyrrolo(1,2-f)phenanthridines as CNS agents
  申请人：PFIZER INC.

  公开号：EP0090526A1

  公开（公告）日：1983-10-05

  1,2,3,4,4a,4b,5,6,7,8,8a,12b-Dodecahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy or alkoxyalkyl) triphenylenes, 2,3,3a,3b,4,5,6,7,7a,11 b-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl) -1H-cyclopenta[1]-phenanthrenes, 2,3,4,4a,4b,5,6,7,8, Sa-decahydro-7- (oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl)-1H-pyrido[1,2-f]phenanthridines, and 1,2,3, 3a, 3b, 4,5,6,7,7a-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-pyrrolo[1,2-f]phenanthridines and derivatives are valuable as central nervous system active agents or as intermediates to compounds having such activity.

  2,3,4,4a,4b,5,6,7,8,Sa-十氢-7-(氧代、羟基或氨基)-9-羟基-11-(烷基、烷氧基、烷氧基烷基、芳基、芳氧基烷基或芳氧基烷基）-1H-吡啶并[1,2-f]菲啶，以及 1,2,3,3a,3b,4,5,6,7,7a-十氢-6-(氧代、羟基或氨基)-8-羟基-10-(烷基、
• EGGLER, J. F.;JOHNSON, M. R.;MELVIN, L. S. ,, JR.
  作者：EGGLER, J. F.、JOHNSON, M. R.、MELVIN, L. S. ,, JR.

  DOI：——

  日期：——